Fennec Pharmaceuticals Inc (FENC) Stock Price, Quote & News

Company Profile

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium...

Industry: Biotechnology

Sector: Healthcare

Phone: 919 636 4530

Website: www.fennecpharma.com

Address:

68 TW Alexander Drive, PO Box 13628, Research Triangle Park, United States

BioTechHealthX Apr. 19 at 2:16 AM

$FENC Fennec Pharmaceuticals (NASDAQ:FENC) is quietly generating revenue with its FDA-approved therapy for pediatric hearing loss. Discover why this under-the-radar biotech stock could be one of the smartest “buy now” plays in a speculative sector shifting toward real-world execution. https://biotechhealthx.com/biotech-news/is-it-a-wise-move-to-invest-in-fennec-pharmaceuticals-fenc/

0 · Reply

RonaldReagan80 Apr. 18 at 12:23 AM

$FENC this is up and coming, watching 😳

0 · Reply

BioTechHealthX Apr. 12 at 2:47 AM

$CRDL $CTMX $FENC $INO $TERN These biotech microcap stocks are flying under the radar but showing massive growth potential. Discover 10 high-risk, high-reward biotech plays that could deliver explosive returns as clinical catalysts approach. https://biotechhealthx.com/biotech-news/top-10-best-biotech-microcap-stocks-that-could-explode-10x-in-2026/

0 · Reply

Eaglelanded Apr. 10 at 8:50 PM

$FENC horribly run - what a pity - such a great opportunity

0 · Reply

focafoca99 Apr. 7 at 9:12 PM

$FENC says the University of Arizona Cancer Center is launching an investigator-sponsored PEDMARK study in AYA and adult cisplatin patients.

0 · Reply

BioTuesdays Apr. 7 at 6:01 PM

$FENC has announced the initiation of an investigator-sponsored study by University of Arizona Cancer Center (UACC) to evaluate use of PEDMARK, a sodium thiosulfate injection, in adolescent and young adult (AYA) and adult patients with head and neck and testicular cancers receiving cisplatin. https://biotuesdays.com/2026/04/07/uacc-initiates-study-of-fennecs-pedmark-for-aya-and-adult-cancers/

0 · Reply

SuperGreenToday Apr. 3 at 12:40 AM

$FENC Share Price: $6.41 Contract Selected: Nov 20, 2026 $10 Calls Buy Zone: $1.15 – $1.42 Target Zone: $2.11 – $2.57 Potential Upside: 73% ROI Time to Expiration: 231 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

BioTechHealthX Mar. 29 at 3:03 PM

$FENC Fennec Pharmaceuticals stands out in biotech by already generating revenue. With a niche oncology product and growing adoption, FENC stock is catching investor attention. https://biotechhealthx.com/biotech-news/is-it-a-good-decision-to-buy-fennec-pharmaceuticals-fenc-shares/

0 · Reply

Stanley229 Mar. 27 at 9:42 AM

$FENC

0 · Reply

Golfskier Mar. 24 at 3:58 PM

$FENC Well, I guess light on revs and the burn was up...right back into the "show me" camp.

0 · Reply

Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026

Apr 7, 2026, 7:03 AM EDT - 5 weeks ago

Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center

Mar 31, 2026, 6:00 AM EDT - 6 weeks ago

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 24, 2026, 1:20 PM EDT - 7 weeks ago

Fennec Pharmaceuticals Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 24, 2026, 8:30 AM EDT - 7 weeks ago

Fennec Pharmaceuticals Earnings Call Transcript: Q4 2025

2026-03-24T11:12:33.000Z - 7 weeks ago

Fennec reports Q4 EPS (17c), consensus 4c

Mar 24, 2026, 7:00 AM EDT - 7 weeks ago

Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 18, 2026, 7:08 AM EDT - 2 months ago

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026

2026-03-16T12:47:13.000Z - 2 months ago

Fennec announces settlement agreement resolving Pedmark litigation

2026-03-04T12:21:07.000Z - 2 months ago

Fennec announces clinical research collaboration with Tampa General Hospital

Mar 4, 2026, 7:05 AM EST - 2 months ago

Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute

2026-02-20T12:23:09.000Z - 2 months ago

Fennec presents real world date on use of Pedmark

2026-02-12T10:15:30.000Z - 3 months ago

Fennec initiated with a Buy at B. Riley

2026-01-09T10:35:13.000Z - 4 months ago

Fennec initiated with an Overweight at Piper Sandler

2026-01-08T22:35:25.000Z - 4 months ago

Fennec initiated with an Overweight at Piper Sandler

Dec 26, 2025, 5:44 PM EST - 4 months ago

Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)

2025-12-09T12:20:57.000Z - 5 months ago

Fennec announces planned initiation of IST by City of Hope to evaluate PEDMARK

Dec 9, 2025, 7:00 AM EST - 5 months ago

Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors

Dec 3, 2025, 1:00 PM EST - 5 months ago

Fennec Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference

2025-12-02T12:05:33.000Z - 5 months ago

Fennec announces Phase 2/3 STS-J01 trial met primary endpoint

Dec 2, 2025, 7:01 AM EST - 5 months ago

Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss

Nov 26, 2025, 5:59 AM EST - 6 months ago

Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference

2025-11-19T12:21:51.000Z - 6 months ago

Fennec completes full debt redemption

Nov 17, 2025, 4:15 PM EST - 6 months ago

Fennec Pharmaceuticals Announces Closing of Offering of Common Shares

Nov 13, 2025, 11:11 PM EST - 6 months ago

Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada

Nov 13, 2025, 11:07 PM EST - 6 months ago

Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares

2025-11-13T21:22:43.000Z - 6 months ago

Fennec announces common shares offering, no amount given

2025-11-13T21:15:51.000Z - 6 months ago

Fennec reports Q3 EPS (2c), consensus (3c)

Nov 13, 2025, 4:08 PM EST - 6 months ago

Fennec Pharmaceuticals Announces Proposed Offering of Common Shares

Sep 9, 2025, 3:00 PM EDT - 8 months ago

Fennec Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

2025-08-15T13:05:27.000Z - 9 months ago

Fennec price target raised to $14 from $13 at Craig-Hallum

2025-08-14T13:40:26.000Z - 9 months ago

Fennec Pharmaceuticals trading resumes

2025-08-14T13:35:39.000Z - 9 months ago

Fennec Pharmaceuticals trading halted, volatility trading pause

Aug 14, 2025, 8:30 AM EDT - 9 months ago

Fennec Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 14, 2025, 6:08 AM EDT - 9 months ago

Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update

Aug 11, 2025, 7:12 AM EDT - 9 months ago

Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025

Jun 3, 2025, 4:31 PM EDT - 1 year ago

Fennec Announces Results of Annual Meeting

May 20, 2025, 3:00 PM EDT - 1 year ago

Fennec Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

2025-05-14T12:54:42.000Z - 1 year ago

Fennec price target raised to $13 from $12 at Craig-Hallum

May 13, 2025, 8:30 AM EDT - 1 year ago

Fennec Pharmaceuticals Earnings Call Transcript: Q1 2025

May 8, 2025, 4:17 PM EDT - 1 year ago

Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

Mar 10, 2025, 8:30 AM EDT - 1 year ago

Fennec Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 10, 2025, 6:03 AM EDT - 1 year ago

Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Mar 6, 2025, 4:22 PM EST - 1 year ago

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025

Feb 7, 2025, 7:00 AM EST - 1 year ago

Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany

Dec 20, 2024, 6:16 AM EST - 1 year ago

Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales

Dec 19, 2024, 6:13 AM EST - 1 year ago

Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management

Dec 12, 2024, 7:01 AM EST - 1 year ago

Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

Nov 7, 2024, 8:30 AM EST - 1 year ago

Fennec Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 7, 2024, 6:13 AM EST - 1 year ago

Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 31, 2024, 6:23 AM EDT - 1 year ago

Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

Oct 28, 2024, 6:23 AM EDT - 1 year ago

Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company's Next Stage of Growth

Sep 11, 2024, 12:00 PM EDT - 1 year ago

Fennec Pharmaceuticals Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 5, 2024, 6:56 AM EDT - 1 year ago

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 13, 2024, 8:30 AM EDT - 1 year ago

Fennec Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 13, 2024, 6:05 AM EDT - 1 year ago

Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 6, 2024, 4:31 PM EDT - 1 year ago

Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024

Aug 5, 2024, 6:26 AM EDT - 1 year ago

Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director

Jul 1, 2024, 6:00 AM EDT - 2 years ago

Fennec Pharmaceuticals Announces Management Change

May 14, 2024, 8:30 AM EDT - 2 years ago

Fennec Pharmaceuticals Earnings Call Transcript: Q1 2024

May 14, 2024, 6:03 AM EDT - 2 years ago

Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024, 6:15 PM EDT - 2 years ago

Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024

Mar 21, 2024, 8:30 AM EDT - 2 years ago

Fennec Pharmaceuticals Earnings Call Transcript: Q4 2023

Mar 21, 2024, 6:00 AM EDT - 2 years ago

Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update

Mar 19, 2024, 6:01 AM EDT - 2 years ago

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024

Mar 17, 2024, 9:00 PM EDT - 2 years ago

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

Feb 29, 2024, 7:04 AM EST - 2 years ago

Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results

Feb 1, 2024, 5:55 AM EST - 2 years ago

FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin

Dec 5, 2023, 5:55 AM EST - 2 years ago

Fennec Announces Incremental $5 Million Investment from Petrichor

Nov 16, 2023, 5:00 AM EST - 2 years ago

Fennec Pharmaceuticals Transcript: 14th Annual Jefferies London Healthcare Conference 2023

Nov 6, 2023, 8:30 AM EST - 2 years ago

Fennec Pharmaceuticals Earnings Call Transcript: Q3 2023

Nov 6, 2023, 5:59 AM EST - 2 years ago

Fennec Pharmaceuticals Announces Third Quarter 2023 Financial Results and Provides Business Update

Oct 30, 2023, 6:45 AM EDT - 2 years ago

Fennec Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 6, 2023

Aug 3, 2023, 8:30 AM EDT - 3 years ago

Fennec Pharmaceuticals Earnings Call Transcript: Q2 2023

Aug 3, 2023, 5:59 AM EDT - 3 years ago

Fennec Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Business Update

Jul 31, 2023, 5:30 AM EDT - 3 years ago

Fennec Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 3, 2023

Jun 6, 2023, 5:44 AM EDT - 3 years ago

Fennec Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

May 11, 2023, 8:30 AM EDT - 3 years ago

Fennec Pharmaceuticals Earnings Call Transcript: Q1 2023

May 11, 2023, 6:01 AM EDT - 3 years ago

Fennec Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

May 8, 2023, 6:15 AM EDT - 3 years ago

Fennec Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023

Mar 31, 2023, 8:03 AM EDT - 3 years ago

Fennec Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

Mar 30, 2023, 5:55 AM EDT - 3 years ago

Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results

BioTechHealthX Apr. 19 at 2:16 AM

0 · Reply

RonaldReagan80 Apr. 18 at 12:23 AM

$FENC this is up and coming, watching 😳

0 · Reply

BioTechHealthX Apr. 12 at 2:47 AM

0 · Reply

Eaglelanded Apr. 10 at 8:50 PM

$FENC horribly run - what a pity - such a great opportunity

0 · Reply

focafoca99 Apr. 7 at 9:12 PM

$FENC says the University of Arizona Cancer Center is launching an investigator-sponsored PEDMARK study in AYA and adult cisplatin patients.

0 · Reply

BioTuesdays Apr. 7 at 6:01 PM

0 · Reply

SuperGreenToday Apr. 3 at 12:40 AM

0 · Reply

BioTechHealthX Mar. 29 at 3:03 PM

0 · Reply

Stanley229 Mar. 27 at 9:42 AM

$FENC

0 · Reply

Golfskier Mar. 24 at 3:58 PM

$FENC Well, I guess light on revs and the burn was up...right back into the "show me" camp.

0 · Reply

ap20 Mar. 24 at 2:46 PM

$FENC Why is this down today? I’m clueless, as usual.

1 · Reply

OpenOutcrier Mar. 24 at 12:44 PM

$FENC (-6.0% pre) Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update https://ooc.bz/l/97013

0 · Reply

ap20 Mar. 24 at 12:24 PM

$FENC Great solid growth. Nice q.

0 · Reply

deedeethegenius Mar. 23 at 7:11 PM

$FENC $CNXC ideas

0 · Reply

JackCampbell Mar. 18 at 2:42 PM

$FENC https://finance.yahoo.com/news/fennec-pharmaceuticals-report-full-fourth-110800755.html

0 · Reply

focafoca99 Mar. 17 at 6:33 AM

$FENC settling the Cipla fight and landing a license deal with Cipla/Cipla USA on the same day is a lot cleaner than the market probably expected.

0 · Reply

OfficialStocktwitsUser Mar. 11 at 1:40 PM

$FENC RSI: 30.00, MACD: -0.0596 Vol: 0.46, MA20: 8.34, MA50: 7.94 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Stanley229 Mar. 2 at 5:52 PM

$FENC why is FENC on its way down? Are we not expecting good Q4 results next week?

1 · Reply

OfficialStocktwitsUser Feb. 27 at 4:02 AM

$FENC RSI: 70.56, MACD: 0.3039 Vol: 0.52, MA20: 8.25, MA50: 7.89 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

prismmarketview Feb. 26 at 5:56 PM

Investing in Innovation during Rare Disease Day 2026 $LRMR $ZVRA $FENC $RZLT $IRD Investing in Innovation during Rare Disease Day 2026 https://prismmarketview.com/investing-in-innovation-during-rare-disease-day-2026/

0 · Reply

BillionerOfKing Feb. 22 at 3:06 AM

$FENC Current Stock Price: $8.72 Contracts to trade: $10.0 FENC Mar 20 2026 Call Entry: $0.45 Exit: $0.72 ROI: 61% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

OpenOutcrier Feb. 20 at 1:25 PM

$FENC (+2.1% pre) Fennec presents real world data on PEDMARK for head and neck cancer patients https://ooc.bz/l/94023

0 · Reply

Market Cap	245.24M
Revenue (ttm)	44.64M
Net Income (ttm)	-9.74M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	31.86
Profit Margin	-21.82%
Debt to Equity Ratio	0.00

Volume	114,100
Avg Vol	183,918
Day's Range	N/A - N/A
Shares Out	34.54M
Stochastic %K	71%
Beta	0.91
Analysts	Strong Sell
Price Target	$15.14